Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

46.46 -2.00 (-4.13%)
Streaming Delayed Price Updated: 3:36 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 39,348,438
Open 47.75
Bid (Size) 46.46 (300)
Ask (Size) 46.47 (500)
Prev. Close 48.46
Today's Range 46.34 - 49.56
52wk Range 45.05 - 112.52
Shares Outstanding N/A
Dividend Yield 4.73%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as... 
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx
The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026. 
Via Benzinga
Topics Government

Performance

YTD
-46.9%
-46.9%
1 Month
-22.1%
-22.1%
3 Month
+2.4%
+2.4%
6 Month
-31.2%
-31.2%
1 Year
-57.8%
-57.8%

More News

Read More
Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.
Via The Motley Fool
Topics Earnings
Trump Announces Deals With Eli Lilly, Novo Nordisk To Lower Obesity Drug Prices
Via Stocktwits
Topics Government
Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years?
Via Stocktwits
Earnings Scheduled For November 5, 2025
Via Benzinga
Trump Slashes Weight-Loss Drug Prices By Up To 74% In Deal With Lilly, Novo
Via Investor's Business Daily
Topics Government
Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits
Via Benzinga
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal
Via Benzinga
Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further
Via Stocktwits
'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera
Via Investor's Business Daily
Eli Lilly And Novo Nordisk Ignite Bullish Retail Frenzy Ahead Of TrumpRx Deals To Slash Prices For Weight-Loss Drugs
Via Stocktwits
Novo Nordisk A/S-Spons ADR (NYSE:NVO) Embodies Affordable Growth Strategy
Via Chartmill
Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes
Via Benzinga
Topics Government
Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal
Via Stocktwits
Topics Law Enforcement
Obesity Drugmakers Face Shifting Tides: Novo Nordisk Plunges While Eli Lilly Soars
Via MarketMinute
Topics Economy
Novo Nordisk Q3 2025 Earnings Call Transcript
Via Benzinga
Topics Earnings
Market Movers: Eli Lilly, Cadre, BP, Kellanova, and Teva Soar to 52-Week Highs Amidst Shifting Economic Tides
Via MarketMinute
Topics Economy Intellectual Property Supply Chain
Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain
Via Benzinga
Prediction: Novo Nordisk Will Soar by 2026
Via The Motley Fool
Novo Nordisk Skids After Cutting Its Outlook For The Third Time This Year
Via Investor's Business Daily
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy
Via The Motley Fool
Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs
Via Benzinga
Here's Why Shares in Viking Therapeutics Shot Higher in October
Via The Motley Fool
Can Novo Nordisk’s ‘Attractive’ Fundamentals Outweigh Slowing Wegovy Sales And A $149 Price Cap?
Via Stocktwits
Topics Lawsuit

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 46.46
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 11/06/25 03:36 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.